Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eNRGy: Zenocutuzumab in NRG1+ Solid Tumors
NCT02912949Phase 2Active, not recruiting
- Start
- Jan 2015
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 2, open-label trial of zenocutuzumab in solid tumor, non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma (PDAC) (3 arms). Primary endpoints: Objective Overall Response Rate at 36 months and Duration of Response at 36 months. Started Jan 2015; status: active, not recruiting.
02
Drugs
zenocutuzumab
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02912949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02912949.